gracenote
All shall be well . . .
- Messages
- 1,537
- Location
- Santa Rosa, CA
The paper asks a lot of very interesting questions which future research will need to answer, hopefully soon.
Pandoras Box?
The proposed pathobiology of XMRV-related viruses in mice and other species opens a Pandoras box of medical issues.
Does XMRV induce a primary immunodeficiency?
Are lymphocytes the primary target cells in the periphery, with microglial or other support cells playing that role in the central nervous system?
Is XMRV neurotropic and capable of inducing the cognitive, autonomic, and nociceptive changes typical of CFS? Are there readily detectable plasma or cerebrospinal fluid biomarkers of XMRV infection, activation, and transmissibility?
How is XMRV spread?
Do the current data implicate transmission by plasma, leukocytes, gammaglobulin, or other blood products?
Are there indications of fatiguing illnesses in clusters of previously healthy individuals who have received blood transfusions?
Is XMRV transmitted sexually or via saliva?
Evidence of infection in 3.7% of the healthy population was presented. Are these individuals at risk for CFS, fibromyalgia, related syndromes, or even leukemia or prostate cancer?
Does XMRV play a role in the CFS that follows immunocompromise by chemotherapy for cancer or lupus?